CA2928665A1 - Formes cristallines de composes therapeutiques et utilisations de celles-ci - Google Patents
Formes cristallines de composes therapeutiques et utilisations de celles-ci Download PDFInfo
- Publication number
- CA2928665A1 CA2928665A1 CA2928665A CA2928665A CA2928665A1 CA 2928665 A1 CA2928665 A1 CA 2928665A1 CA 2928665 A CA2928665 A CA 2928665A CA 2928665 A CA2928665 A CA 2928665A CA 2928665 A1 CA2928665 A1 CA 2928665A1
- Authority
- CA
- Canada
- Prior art keywords
- less
- equal
- crystalline form
- pharmaceutical composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3109285A CA3109285A1 (fr) | 2013-11-01 | 2014-11-03 | Formes cristallines de composes therapeutiques et utilisations de celles-ci |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361898741P | 2013-11-01 | 2013-11-01 | |
US61/898,741 | 2013-11-01 | ||
US14/184,886 | 2014-02-20 | ||
US14/184,886 US9353123B2 (en) | 2013-02-20 | 2014-02-20 | Therapeutic compounds and uses thereof |
PCT/US2014/063630 WO2015066584A1 (fr) | 2013-11-01 | 2014-11-03 | Formes cristallines de composés thérapeutiques et utilisations de celles-ci |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3109285A Division CA3109285A1 (fr) | 2013-11-01 | 2014-11-03 | Formes cristallines de composes therapeutiques et utilisations de celles-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2928665A1 true CA2928665A1 (fr) | 2015-05-07 |
Family
ID=53005242
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3109285A Abandoned CA3109285A1 (fr) | 2013-11-01 | 2014-11-03 | Formes cristallines de composes therapeutiques et utilisations de celles-ci |
CA2928665A Abandoned CA2928665A1 (fr) | 2013-11-01 | 2014-11-03 | Formes cristallines de composes therapeutiques et utilisations de celles-ci |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3109285A Abandoned CA3109285A1 (fr) | 2013-11-01 | 2014-11-03 | Formes cristallines de composes therapeutiques et utilisations de celles-ci |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3062795A4 (fr) |
JP (2) | JP6426195B2 (fr) |
AU (1) | AU2014341966B2 (fr) |
CA (2) | CA3109285A1 (fr) |
WO (1) | WO2015066584A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3109285A1 (fr) * | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Formes cristallines de composes therapeutiques et utilisations de celles-ci |
JP7108681B2 (ja) | 2017-08-11 | 2022-07-28 | アモーレパシフィック コーポレーション | (r)‐n‐[1‐(3,5‐ジフルオロ‐4‐メタンスルホニルアミノ‐フェニル)‐エチル]‐3‐(2‐プロピル‐6‐トリフルオロメチル‐ピリジン‐3‐イル)‐アクリルアミドを含む医薬組成物 |
WO2020179837A1 (fr) | 2019-03-04 | 2020-09-10 | Ricoh Company, Ltd. | Appareil et procédé de traitement de coopération |
GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080015482A (ko) * | 1999-02-10 | 2008-02-19 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
CA2473572C (fr) * | 2002-02-01 | 2011-05-10 | Astrazeneca Ab | Composes de quinazoline |
CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
JP2008515961A (ja) * | 2004-10-12 | 2008-05-15 | アストラゼネカ アクチボラグ | 癌に対する使用のためのキナゾリン誘導体 |
AU2014219024B2 (en) * | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
CA3109285A1 (fr) * | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Formes cristallines de composes therapeutiques et utilisations de celles-ci |
-
2014
- 2014-11-03 CA CA3109285A patent/CA3109285A1/fr not_active Abandoned
- 2014-11-03 EP EP14857110.2A patent/EP3062795A4/fr not_active Withdrawn
- 2014-11-03 JP JP2016552430A patent/JP6426195B2/ja active Active
- 2014-11-03 WO PCT/US2014/063630 patent/WO2015066584A1/fr active Application Filing
- 2014-11-03 CA CA2928665A patent/CA2928665A1/fr not_active Abandoned
- 2014-11-03 AU AU2014341966A patent/AU2014341966B2/en active Active
-
2018
- 2018-10-24 JP JP2018199872A patent/JP2019038824A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019038824A (ja) | 2019-03-14 |
AU2014341966B2 (en) | 2017-08-17 |
EP3062795A4 (fr) | 2017-05-31 |
WO2015066584A1 (fr) | 2015-05-07 |
CA3109285A1 (fr) | 2015-05-07 |
JP6426195B2 (ja) | 2018-11-21 |
AU2014341966A1 (en) | 2016-05-12 |
JP2016535779A (ja) | 2016-11-17 |
EP3062795A1 (fr) | 2016-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11713323B2 (en) | Crystalline forms of therapeutic compounds and uses thereof | |
CA2871748C (fr) | Nanoparticules pharmaceutiques a transport mucosal ameliore | |
US9688688B2 (en) | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof | |
JP7058885B2 (ja) | 尿素誘導体及びその使用 | |
JP2019038824A (ja) | 治療用化合物の結晶形態及びその使用 | |
US20190023710A1 (en) | Novel compounds and uses thereof | |
US9890173B2 (en) | Crystalline forms of therapeutic compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20210217 |